Skip to main navigation
Skip to search
Skip to main content
Manipal Academy of Higher Education, Manipal, India Home
Help & FAQ
Home
Profiles
Research units
Research output
Equipment
Search by expertise, name or affiliation
Alirocumab—a novel drug for familial hypercholesterolemia
Priyanka Kamath
,
Preethi J. Shenoy
*
*
Corresponding author for this work
Department of Pharmacology, Kasturba Medical College, Mangalore
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Alirocumab—a novel drug for familial hypercholesterolemia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
INIS
drugs
100%
density
100%
lipoproteins
100%
patients
75%
cholesterol
75%
levels
25%
gain
25%
doses
25%
adults
25%
therapy
25%
inhibition
25%
injection
25%
clinical trials
25%
morbidity
25%
mutations
25%
diet
25%
lipids
25%
processing
25%
hepatocytes
25%
monoclonal antibodies
25%
uptake
25%
us fda
25%
cardiovascular diseases
25%
Medicine and Dentistry
Familial Hypercholesterolemia
100%
Low Density Lipoprotein Cholesterol
40%
Statin
40%
Low-Density Lipoprotein
40%
Apoplexy
20%
Hypolipidemic Agent
20%
Hepatocyte
20%
Adverse Event
20%
Cardiovascular Disease
20%
Prematurity
20%
Myocardial Infarction
20%
Clinical Trial
20%
Myalgia
20%
Fatality
20%
Pruritus
20%
Drug Choice
20%
Gain of Function Mutation
20%
Injection Site Reaction
20%
Alirocumab
20%
Monoclonal Antibody
20%
Pharmacology, Toxicology and Pharmaceutical Science
Familial Hypercholesterolemia
100%
Low Density Lipoprotein Cholesterol
40%
Low Density Lipoprotein
40%
Clinical Trial
20%
Drug Choice
20%
Antilipemic Agent
20%
Statin (Protein)
20%
Adverse Event
20%
Pruritus
20%
Prematurity
20%
Heart Infarction
20%
Fatality
20%
Coronary Artery Atherosclerosis
20%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
20%
Myalgia
20%
Cerebrovascular Accident
20%
Alirocumab
20%
Monoclonal Antibody
20%
Injection Site Reaction
20%
Cardiovascular Disease
20%